BM-1244

BM-1244 (APG-1252-M1) is a Bcl-xL/Bcl-2 inhibitor with Kis of 134 nM and 450 nM. BM-1244 has anti-tumor effects by inducing apoptosis and suppressing tumor growth. BM-1244 can induce cytochrome C and Smac release from mitochondria with caspase-3 and PARP cleavage. BM-1244 exhibits synergy with chemotherapy in vivo. BM-1244 can be studied in research for colorectal cancer, acute myeloid leukemia and gastric cancer[1][2][3].

Product Specifications

CAS Number

[1619923-32-8]

Product Name Alternative

APG-1252-M1

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family; Caspase; PARP

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bm-1244.html

Concentration

10mM

Purity

99.85

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

O=C(C1CCN(CC[C@@H](NC2=CC=C(S(=O)(NC3=CC=C(N4CCN(C5=CC(F)=CC(C6=C(C7=CC=C(Cl)C=C7)N(C(C)C)C(C)=C6S(=O)(C)=O)=C5)CC4)C=C3)=O)C=C2S(=O)(C(F)(F)F)=O)CSC8=CC=CC=C8)CC1)O

Molecular Formula

C54H59ClF4N6O8S4

Molecular Weight

1159.79

References & Citations

[1]Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun. 2005;333 (2) :336-343.|[2]Yi, H., et al., (2020) . Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer medicine, 9 (12), 4197-4206. |[3]Yao, W., et al., (2022) . Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis. Neoplasia (New York, N.Y.), 29, 100798.